Somilo O. V., Kalbus O. I.
SEASONAL CHARACTERISTICS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS COURSE
Show/Download
About the author:
Somilo O. V., Kalbus O. I.
Heading:
CLINICAL AND EXPERIMENTAL MEDICINE
Type of article:
Scientific article
Annotation:
This study aimed to determine the seasonal features of the debut and clinical course of relapsing-remitting multiple sclerosis (RRMS). This study examined 105 patients with RRMS aged 18 to 49 years. A clinical and neurological examination was conducted, which included the collection of complaints, anamnesis of the disease (including clarification of the month of disease onset and last exacerbation, as well as the use of disease-modifying therapy), information about the patient's life, and a neurological examination with an EDSS score. The study showed that most patients surveyed (23.8%) had their RRMS debut in March. The most common months for the first symptoms of the disease were March (23.8%), February (16.2%) and May (12.4%), indicating a tendency for the disease to debut in spring (41.0% overall). The frequency of exacerbations in the last year was 48.6% (95% CI 39.0 - 58.1) among all subjects. Most exacerbations were observed in spring (34.3%), with a peak in April (12.4%). Patients taking disease-modifying therapy had the lowest exacerbation rate of 8.5% (95% CI 0.53 - 16.49), while among those not taking such therapy, it was 81.0% (95% CI 70.95 - 91.12), exceeding (p<0.001) the exacerbation rate in patients taking disease-modifying therapy by 72.5% (95% CI 55.3 - 83.5). There was also a statistically significant association between the month of diagnosis and the number of exacerbations in the last year (rs=0.21; p=0.032). According to the results obtained, most often, multiple sclerosis (MS) among patients in the general sample began to develop in the spring. At the same time, the diagnosis was made more often in autumn. It was found that a significantly higher frequency of exacerbations was observed in the spring months. Taking disease-modifying therapy substantially reduces the risk of exacerbations.
Tags:
Bibliography:
- Somilo OV, Kalbus OI, Makarov SO, Sorokin AV, Shastun NP. Prognosis of disability in relapsing-remitting multiple sclerosis. World of Medicine and Biology. 2023;19(84):147. DOI: 10.26724/2079-8334-2023-2-84-147-152.
- Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: A population-based cohort study of 22 million individuals in the UK. The Lancet. 2023;401(10391):1878-90. DOI: 10.1016/s0140-6736(23)00457-9.
- Ebi KL, Capon A, Berry P, Broderick C, de Dear R, Havenith G, et al. Hot weather and heat extremes: Health risks. The Lancet. 2021;398(10301):698-708. DOI: 10.1016/s0140-6736(21)01208-3.
- Sebastian P, Cherbuin N, Barcellos LF, Roalstad S, Casper C, Hart J, et al. Association between time spent outdoors and risk of multiple sclerosis. Neurology. 2022;98(3):e267-e278. DOI: 10.1212/wnl.0000000000013045.
- Nabizadeh F, Valizadeh P, Yazdani Tabrizi M, Moayyed K, Ghomashi N, Mirmosayyeb O. Seasonal and monthly variation in multiple sclerosis relapses: a systematic review and meta-analysis. Acta Neurol Belg. 2022;122(6):1447-1456. DOI: 10.1007/s13760-022-02103-y.
- Yousfi N, Mrabet S, Ben Saad H, Chamari K. Investigating the potential link between lunar cycle and multiple sclerosis relapses: a call for further studies. Libyan J Med. 2023;18(1):2238354. DOI: 10.1080/19932820.2023.2238354.
- Jeanjean M, Bind M-A, Roux J, Ongagna J-C, de Sèze J, Bard D, et al. Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses. Environmental Research. 2018;163:43-52. DOI: 10.1016/j. envres.2018.01.040.
- Feige J, Moser T, Bieler L, Schwenker K, Hauer L, Sellner J. Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. Nutrients. 2020;12(3):783. DOI: 10.3390/nu12030783.
Publication of the article:
«Bulletin of problems biology and medicine», 2023 Issue 3, 170, 264-271 pages, index UDC 616.832-004.21
